Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 5/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350331 | 0.80 | KDM4E (0.39) | KDM4EL3MBTL1S1PR1 | |
| SCHEMBL5532108 | 0.74 | KMT2A (0.40) | SMN1; SMN2KDM4EKMT2AL3MBTL1 | |
| SCHEMBL5538589 | 0.73 | KDM4E (0.42) | CETPKDM4EKMT2AL3MBTL1 | |
| SCHEMBL5532350 | 0.73 | KDM4E (0.42) | CETPKDM4EKMT2AL3MBTL1 | |
| SCHEMBL5537288 | 0.73 | KDM4E (0.42) | CETPKDM4EKMT2AL3MBTL1 | |
| SCHEMBL5538139 | 0.73 | KDM4E (0.42) | CETPKDM4EKMT2AL3MBTL1 | |
| SCHEMBL5537407 | 0.73 | KDM4E (0.42) | CETPKDM4EKMT2AL3MBTL1 | |
| SCHEMBL5538868 | 0.73 | KDM4E (0.42) | CETPKDM4EKMT2AL3MBTL1 | |
| SCHEMBL5538097 | 0.73 | KDM4E (0.42) | CETPKDM4EKMT2AL3MBTL1 | |
| SCHEMBL5535471 | 0.73 | KDM4E (0.42) | CETPKDM4EKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008325-B2 | Plasma carboxypeptidase B inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-30 | — | — | US | claimed |
| JP-4472997-B2 | — | — | 2010-06-02 | — | — | JP | claimed |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | BUCKMAN BRAD | 2009-04-09 | — | — | US | claimed |
| EP-1874322-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-09 | — | — | EP | claimed |
| EP-1817041-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-15 | — | — | EP | claimed |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | claimed |
| WO-2006113247-A1 | USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-26 | — | — | WO | claimed |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | US | claimed |
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | claimed |
| WO-2006041808-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-20 | — | — | WO | claimed |
| JP-2006504622-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1497300-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | Schering Aktiengesellschaft (DE) | 2005-01-19 | — | — | EP | claimed |
| WO-2003080631-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | WO | claimed |
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | BUCKMAN BRAD (US) | 2011-12-29 | — | — | US | disclosed |
| US-8008325-B2 | Plasma carboxypeptidase B inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-2204373-A1 | Phosphonic acid as Plasma Carboxypeptidase B Inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-07-07 | — | — | EP | disclosed |
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | US | disclosed |
| WO-2006041808-A2 | TAFI INHIBITORS AND THEIR USE TO TREAT PULMONARY FIBROSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-20 | — | — | WO | disclosed |
| EP-1497300-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | Schering Aktiengesellschaft (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080631-A2 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105995-A1 | TAFI inhibitors and their use to treat pulmonary fibrosis | SERPINB1, TFPI, TFPI2 | CETP 423/4885CYP2C19 1757/4885CYP1A2 1968/4885 |
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | CPB1, CPB2, CPA1 | CETP 221/4885CYP2C19 267/4885CYP1A2 774/4885 |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | CPB1, CPB2, CPA1 | CETP 221/4885CYP2C19 267/4885CYP1A2 774/4885 |
| US-20060234986-A1 | Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI | TFPI, TFPI2, TNNI3 | CETP 179/4885CYP2C19 2215/4885CYP1A2 3752/4885 |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | CPB1, CPB2, CPA1 | CETP 194/4885CYP2C19 288/4885CYP1A2 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.